î
îŒ
î
Neurosense Therapeutics Ltd
NRSNî¹
詳现ãã£ãŒãã衚瀺
1.220USD
+0.010+0.83%
çµå€Â 09/19, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
30.01Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+0.83%
5æ¥é
0.00%
1ã¶æ
+5.17%
6ã¶æ
+13.92%
幎åæ¥
+1.67%
1幎é
-9.63%
詳现ãã£ãŒãã衚瀺
TradingKey æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2025-09-19äž»èŠã€ã³ãµã€ã
å瀟ã®æ ªäŸ¡ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããŸããæ©é¢æè³å®¶ã«ããèªç¥åºŠã¯éåžžã«é«ãã§ããéå»30æ¥éã§ãè€æ°ã®ã¢ããªã¹ããå瀟ãè²·ããšè©äŸ¡ããŸãããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
æ ªåŒã¹ã³ã¢î°î°
æ¯æç·ãšæµæç·
ããŒã¿ãªã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¢ããªã¹ãç®æšæ ªäŸ¡
2
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
14.000
ç®æšæ ªäŸ¡
+1057.02%
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
äŒæ¥ãã€ã©ã€ã
匷ã¿ãªã¹ã¯
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
å²å®
å瀟ã®ææ°ã®PEã¯-3.38ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®è²·ãå¢ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯7.64Mæ ªã§ãåååææ¯ã§1.85%å¢å ããŠããŸãã
ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ãä¿æ
ã¹ã¿ãŒæè³å®¶ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ã¯æ¬éæã0.00æ ªä¿æããŠããŸãã
ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
ããŒã¿ãªã
ç·å£²äžé«
ããŒã¿ãªã
äŒæ¥åî
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
äŒæ¥ã³ãŒãNRSN
äŒæ¥åNeurosense Therapeutics Ltd
æé«çµå¶è²¬ä»»è
ãCEOãMr. Alon Ben-Noon
ãŠã§ããµã€ãhttps://www.neurosense-tx.com/
é¢é£éèåå
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%人æ°éæ
115801.55
+488.98Â (+0.42%)
4474.64
+18.02Â (+0.40%)
3685.06
+40.47Â (+1.11%)
62.207
-0.974Â (-1.54%)
1.17440
-0.00422Â (-0.36%)
147.896
-0.093Â (-0.06%)
43.050
+1.254Â (+3.00%)
0.65858
-0.00255Â (-0.39%)
1.34661
-0.00879Â (-0.65%)
602.10
+2.60Â (+0.43%)
